Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Karyopharm raises $10mm through Series A2 round

Executive Summary

Karyopharm Therapeutics Inc. (cancer, dermatology, inflammatory, and viral disease drug development) raised $10mm through its Series A2 round led by original Series A investor Chione Ltd. Proceeds will be used to advance the company's first oral selective inhibitor of nuclear transport (SINE) candidate into Phase I trials for hematologic cancers and solid tumors. Karyopharm was formed in 2008 and raised $20mm in its Series A exactly one year ago.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies